Pharmaceutical aspects of drug eluting stents
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 97 (12) , 5047-5060
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injuryAdvanced Drug Delivery Reviews, 2006
- Drug-eluting stents: an innovative multidisciplinary drug delivery platformAdvanced Drug Delivery Reviews, 2006
- Restenosis related to percutaneous coronary intervention has been solved?Annals of Medicine, 2006
- Molecular Basis of Restenosis and Drug-Eluting StentsCirculation, 2005
- Drug-eluting stents: results, promises and problemsInternational Journal of Cardiology, 2005
- Physical characterization of controlled release of paclitaxel from the TAXUS™ Express2™ drug‐eluting stentJournal of Biomedical Materials Research Part A, 2004
- Atherosclerotic Vascular Disease ConferenceCirculation, 2004
- Interventional treatment of coronary heart disease and peripheral vascular disease.Circulation, 2000
- The comparative pathobiology of atherosclerosis and restenosisThe American Journal of Cardiology, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999